"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,GB,A,GB 1271693 A,060-429-433-855-855,1972-04-26,1972,GB 3194869 A,1969-06-24,GB 3194869 A,1969-06-24,MUSICAL TUNING AIDS,"1,271,693. Tuning aids. W. H. JARVIS, and G. GARTON. 24 Sept., 1970 [24 June, 1969], No. 31948/69. Heading G5J. An electrical signal derived from a musical instrument to be tuned is applied to one pair of plates of a cathode-ray tube 6, the output from an oscillator being applied to the other pair. The oscillator may consist of a tuning fork 1, detector coil 2, amplifier 3 and drive coil 4. The signal is fed via transformer 9 to the X-X deflection plates 7. Alternatively, the oscillator may consist of a crystal controlled oscillator (not shown) feeding a divider chain having twelve outputs (not shown). The signal from the musical instrument may be picked up by a microphone 10, fed into an amplifier 11, and passed via transformer 12 to the Y-Y deflection plates 9. Alternatively, jacks may be used, at 13 to pick up the signal, and at 14 to connect to a drive coil to sustain the oscillations of the musical instrument, when an electric musical instrument such as an electric guitar is used. Power for the amplifiers 3, and 11, and the cathode-ray tube 6 is provided by a transformer 15. When the musical instrument is in tune with the oscillator, a Lissajous figure in the form of an elllipse will be produced on the screen of the cathode-ray tube.",JARVIS WILLIAM HUGH;;GARTON GRAHAM,JARVIS WILLIAM HUGH;;GARTON GRAHAM,,https://lens.org/060-429-433-855-855,Granted Patent,no,0,0,1,1,0,G10H1/44,G10H1/44,G5J JCTA          JCTA;;G5J J45           J45,0,0,,,,EXPIRED
2,IT,A0,IT 8219282 A0,150-232-627-840-858,1982-01-25,1982,IT 1928282 A,1982-01-25,GB 8102281 A;;US 29826981 A;;US 31909081 A,1981-01-26,"RICERCA TABELLARE DI FUNZIONI NONLINEARI UTILIZZANDO MEMORIE DI SOLA LETTURA, DI DIMENSIONI RIDOTTE.",,RCA CORP,CHRISTOPHER HUGH STROLLE;;TERRENCE RAYMOND SMITH;;HENRY GARTON LEWIS JR;;ALFONSE ACAMPORA,,https://lens.org/150-232-627-840-858,Patent Application,no,0,0,7,27,0,G06F1/0307;;G06F1/0353;;G06F1/0356;;G06F2101/04;;G06F2101/08;;G06F2101/10;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/646;;H04N9/78,G06F1/03;;G06F1/035;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/64;;H04N9/78,,0,0,,,,DISCONTINUED
3,EP,A4,EP 0070311 A4,154-432-581-592-095,1985-06-06,1985,EP 82900743 A,1982-01-25,GB 8102281 A;;US 29826981 A;;US 31909081 A,1981-01-26,TABLE LOOK-UP OF NON-LINEAR FUNCTIONS USING REDUCED-SIZED ROM.,,RCA CORP,STROLLE CHRISTOPHER HUGH;;SMITH TERRANCE RAYMOND;;LEWIS HENRY GARTON JR;;ACAMPORA ALFONSE;;REITMEIER GLENN ARTHUR,RCA CORPORATION (1985-06-26),https://lens.org/154-432-581-592-095,Search Report,no,5,0,7,27,0,G06F1/0307;;G06F1/0353;;G06F1/0356;;G06F2101/04;;G06F2101/08;;G06F2101/10;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/646;;H04N9/78,G06F1/03;;G06F1/035;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/64;;H04N9/78,,0,0,,,,DISCONTINUED
4,WO,A1,WO 1982/002637 A1,188-831-925-601-429,1982-08-05,1982,US 8200086 W,1982-01-25,GB 8102281 A;;US 29826981 A;;US 31909081 A,1981-01-26,TABLE LOOK-UP OF NON-LINEAR FUNCTIONS USING REDUCED-SIZED ROM,"A digital memory (10) which contains digital data words representative of a desired symmetrical transfer characteristic of a digital signal processor. Digital signals which are to be processed are applied to the address inputs of the memory (10), producing output signals in conformance with the desired transfer characteristic. Advantage is taken of the symmetrical nature of the response characteristic to minimize the size of the memory. Data words corresponding to only a portion of the full dynamic range of the digital signal processor are stored in the memory (10), and memory locations are addressed and read out in accordance with the value of a polarity-determining bit of the input digital signal, with the output signals being translated over the required full dynamic range in accordance with the value of the polarity-determining bit. In a preferred embodiment of the invention, the memory (10) is a random access memory, with stored data values being altered in response to a user control to change the transfer characteristic of the processor.",RCA CORP,STROLLE CHRISTOPHER HUGH;;SMITH TERRANCE RAYMOND;;LEWIS HENRY GARTON JR;;ACAMPORA ALFONSE;;REITMEIER GLENN ARTHUR,,https://lens.org/188-831-925-601-429,Patent Application,yes,4,11,7,27,0,G06F1/0307;;G06F1/0353;;G06F1/0356;;G06F2101/04;;G06F2101/08;;G06F2101/10;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/646;;H04N9/78,G06F1/03;;G06F1/035;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/64;;H04N9/78,G4A ACX           CX,0,0,,,,PENDING
5,EP,A1,EP 0070311 A1,012-102-611-927-474,1983-01-26,1983,EP 82900743 A,1982-01-25,GB 8102281 A;;US 29826981 A;;US 31909081 A,1981-01-26,TABLE LOOK-UP OF NON-LINEAR FUNCTIONS USING REDUCED-SIZED ROM.,"Memoire numerique (10) qui contient des mots de donnees numeriques representant une caracteristique de transfert symetrique desiree d'un processeur de signaux numeriques Les signaux numeriques a traiter sont appliques aux entrees d'adresses de la memoire (10), produisant des signaux de sortie en conformite avec la caracteristique de transfert desiree. On tire avantage de la nature symetrique de la caracteristique de reponse afin de reduire au minimum les dimensions de la memoire. Les mots de donnees qui ne correspondent qu'a une partie de la gamme dynamique du processeur de signaux numeriques sont stockes dans la memoire (10), et les emplacements de memoire sont adresses et extraits en fonction de la valeur d'un bit de determination de la polarite du signal numerique d'entree, les signaux de sortie etant traduits sur la gamme dynamique requise en fonction de la valeur du bit de determination de la polarite. Dans un mode d'execution prefere de l'invention, la memoire (10) est une memoire a acces selectif, les donnees stockees etant modifiees en reponse a une commande de l'utilisateur en vue de changer la caracteristique de transfert du processeur.",RCA CORP,STROLLE CHRISTOPHER HUGH;;SMITH TERRANCE RAYMOND;;LEWIS HENRY GARTON JR;;ACAMPORA ALFONSE;;REITMEIER GLENN ARTHUR,RCA CORPORATION (1985-06-26),https://lens.org/012-102-611-927-474,Patent Application,yes,0,0,7,27,0,G06F1/0307;;G06F1/0353;;G06F1/0356;;G06F2101/04;;G06F2101/08;;G06F2101/10;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/646;;H04N9/78,G06F1/03;;G06F1/035;;G06T3/00;;G09G5/395;;G11C7/00;;G11C8/04;;G11C8/16;;H04N9/64;;H04N9/78,,0,0,,,,DISCONTINUED
6,WO,A3,WO 2007/084667 A3,047-421-488-716-169,2007-12-06,2007,US 2007/0001439 W,2007-01-18,US 76012406 P,2006-01-19,FUSED HETEROBICYCLIC KINASE INHIBITORS,"Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.",OSI PHARMACEUTICAL INC;;ARNOLD LEE D;;CHEN XIN;;DONG HANPING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SMITH COLIN PETER SAMBROOK;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,ARNOLD LEE D;;CHEN XIN;;DONG HANPING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SMITH COLIN PETER SAMBROOK;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,,https://lens.org/047-421-488-716-169,Search Report,yes,11,0,8,8,0,A61P9/00;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/06;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/437;;A61P35/00,,12,2,031-381-001-179-580;;186-721-359-209-640,10.1055/s-2001-13366;;10779382,"DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450514, Database accession no. 1209753 (BRN);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450515, Database accession no. 7760877 (BRN);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450516, Database accession no. 109568 (BRN);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450517, Database accession no. 9908322, 9915660, 9931124, 9936785 (BRNs);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450518, Database accession no. 606575 (BRN);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450519, Database accession no. 781534, 788158, 797421, 811229 (BRNs);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450520, Database accession no. 1104617, 1213590, 3608185, 3608868 (BRNs);;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450521;;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450522, Database accession no. 109667 (BRN);;ALLEGRETTI, M. ET AL.: ""PALLADIUM-CATALYSED FUNCTIONALISATION AT 4- AND 6- POSITION OF THE 7-AZAINDOLE SYSTEM"", SYNLETT, THIEME INTERNATIONAL, STUTTGART, DE, vol. 5, 2001, pages 609 - 612, XP001205419, ISSN: 0936-5214;;ISHIZAKI, T. ET AL.: ""PHARMACOLOGICAL PROPERTIES OF Y-27632, A SPECIFIC INHIBITOR OF RHO-ASSOCIATED KINASES"", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 57, no. 5, May 2000 (2000-05-01), pages 976 - 983, XP008003729, ISSN: 0026-895X;;DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002450523, Database accession no. 5471396 (BRN)",PENDING
7,TW,A,TW 200738709 A,059-398-094-023-899,2007-10-16,2007,TW 96101975 A,2007-01-18,US 76012406 P,2006-01-19,Fused heterobicyclic kinase inhibitors,"Compounds of the formula, and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.",OSI PHARM INC,ARNOLD LEE D;;CHEN XIN;;DONG HANQING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SAMBROOK SMITH COLIN PETER;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,,https://lens.org/059-398-094-023-899,Patent of Addition,no,0,1,8,8,0,A61P9/00;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/06;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/437;;A61P35/00,,0,0,,,,PENDING
8,WO,A2,WO 2007/084667 A2,074-556-930-166-76X,2007-07-26,2007,US 2007/0001439 W,2007-01-18,US 76012406 P,2006-01-19,FUSED HETEROBICYCLIC KINASE INHIBITORS,"Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.",OSI PHARMACEUTICAL INC;;ARNOLD LEE D;;CHEN XIN;;DONG HANPING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SMITH COLIN PETER SAMBROOK;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,ARNOLD LEE D;;CHEN XIN;;DONG HANPING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SMITH COLIN PETER SAMBROOK;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,,https://lens.org/074-556-930-166-76X,Patent Application,yes,0,99,8,8,0,A61P9/00;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/06;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/437;;A61P35/00,,0,0,,,,PENDING
9,CA,A1,CA 2635899 A1,195-576-831-265-549,2007-07-26,2007,CA 2635899 A,2007-01-18,US 76012406 P;;US 2007/0001439 W,2006-01-19,FUSED HETEROBICYCLIC KINASE INHIBITORS,,OSI PHARM INC,THOMAS GERARD HUGH;;GARTON ANDREW;;WANG JING;;ARNOLD LEE D;;KRULLE THOMAS MARTIN;;CHEN XIN;;SMITH COLIN PETER SAMBROOK;;DONG HANPING;;MULVIHILL MARK JOSEPH,,https://lens.org/195-576-831-265-549,Patent Application,no,0,0,8,8,0,A61P9/00;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/06;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/437;;A61P35/00,,0,0,,,,DISCONTINUED
10,EP,A2,EP 1979353 A2,144-032-437-990-464,2008-10-15,2008,EP 07718344 A,2007-01-18,US 2007/0001439 W;;US 76012406 P,2006-01-19,FUSED HETEROBICYCLIC KINASE INHIBITORS,,OSI PHARM INC,ARNOLD LEE D;;CHEN XIN;;DONG HANPING;;GARTON ANDREW;;MULVIHILL MARK JOSEPH;;SAMBROOK-SMITH COLIN PETE;;THOMAS GERARD HUGH;;KRULLE THOMAS MARTIN;;WANG JING,,https://lens.org/144-032-437-990-464,Patent Application,yes,0,0,8,8,0,A61P9/00;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P31/00;;A61P31/04;;A61P31/12;;A61P35/00;;A61P37/06;;C07D471/04;;C07D471/04,C07D471/04;;A61K31/437;;A61P35/00,,1,0,,,See references of WO 2007084667A3,DISCONTINUED
